EGFR and neoplasm: We discovered that prior [neratinib + valproate] exposure results in a re-programing of tumor cells that survived and re-grew, with cells expressing less ERBB1, K-RAS and N-RAS, and having reduced the expression of multiple HDAC proteins that regulate tumor cell immunogenicity.